Professor Mariko Harada-Shiba, MD, PhD

Professor, Cardiovascular Center, Osaka Medical and Pharmaceutical University, Japan

Mariko Harada-Shiba is a lipidologist and a Professor of Cardiovascular Center, Osaka Medical and Pharmaceutical University in Osaka with a particular interest and expertise in dyslipidemia including familial hypercholesterolemia. She has been a Chairperson of the Intractable Disease in Dyslipidemia Project sponsored by the Ministry of Health and Welfare of Japan and working on the project of registry, establishment of disease treatment system, disease awareness and making diagnosis criteria of intractable dyslipidemias including familial hypercholesterolemia, Tangier disease, LCAT deficiency, familial hypobetalipoproteinemia, abetalipoproteinemia　 and primary familial chylomicronemia. She also has been involved in the development of nucleic acid drugs and a founder and outside director of a venture company, Liid Pharmaceuticals.

Dr. Mariko Harada-Shiba received her MD from Shiga University of Medical Science in 1984 and PhD in 1988. She then held a Post-Doctoral and Research Associate position in the Department of Etiology and Pathophysiology (Dr. Akira Yamamoto’s lab) in National Cardiovascular Center and studied lipoprotein metabolism in vivo and in vitro. She was also involved in the treatment of familial hypercholesterolemia including lipoprotein apheresis. In 1996, she joined the Department of Biochemistry (Dr. Richard Hanson’s lab) in Case Western Reserve University in USA and was involved in the project of the development of gene therapy for 2 years. Since coming back to Japan, she has been devoted to clinical and basic FH studies. She has been a chair of Japanese FH guideline committee and was involved in the establishment of Japanese guideline. She was the Director of the Department of Molecular Innovation in Lipidology in National Cerebral and Cardiovascular Center Research Institute for 9 years.

Dr. Mariko Harada-Shiba has been the vice president of International Apheresis Society and Japanese Atherosclerosis Society since 2021. She is also a member of the Science Council of Japan.